Join
Live feed
·
PRReleasevia Quantisnow
Lantern Pharma Inc. logo

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
LTRN· Lantern Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LTRN (Lantern Pharma Inc.) and more on Quantisnow.